CSL shares have fallen almost 40% in 2025. Investors are now asking if the worst is already behind the stock. CSL shares fell nearly 40% in 2025 due to underwhelming profit guidance, elevated costs, ...

CSL shares have dropped significantly in 2025, reaching a seven-year low, due to restructuring and downgraded growth prospects. The company’s core business is robust, with ongoing global demand and ...

CSL is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in ...

Forget one of one: this particular BMW 3.0 CSL is, quite literally, the very first M race car, and it’s up for sale for presumably many dollars. The very first official BMW M project was the 3.0 CSL.

Our fair value estimate is 30% higher than CSL's analyst price target of US$248 In this article we are going to estimate the intrinsic value of CSL Limited (ASX:CSL) by projecting its future cash ...

Nov 18 (Reuters) - Australian biotech firm CSL (CSL.AX), opens new tab said on Tuesday it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, in a move to expand its ...

SYDNEY--Australia-based pharmaceutical company CSL plans to expand its U.S. production over the next five years as part of a $1.5 billion investment in the country. CSL, which produces plasma-derived ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company announced in August ...

CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention. A recovery ...

As an Amazon Associate, we earn from qualifying purchases. TweakTown may also earn commissions from other affiliate partners at no extra cost to you. For cross-platform compatibility, the Fanatec GT ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Australian biotechnology ...

CSL has moved quickly to spend some of the money freed up by recent cuts, securing an option to buy the phase 3-ready blood clotting specialist VarmX in return for $117 million upfront. Last month, ...